Maximizing the impact of the Cures Acceleration Network : : accelerating the development of new drugs and diagnostics : workshop summary / / Steve Olson and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies.

Advances in technologies and knowledge are creating new avenues for research and opportunities for the discovery and clinical development of innovative therapies and diagnostics. However, despite these opportunities, only a small fraction of investigational products are successfully developed into c...

Full description

Saved in:
Bibliographic Details
TeilnehmendeR:
Place / Publishing House:Washington, District of Columbia : : National Academies Press,, [2012]
2012
Year of Publication:2012
Language:English
Online Access:
Physical Description:1 online resource (131 pages)
Tags: Add Tag
No Tags, Be the first to tag this record!
id 5003379066
ctrlnum (MiAaPQ)5003379066
(Au-PeEL)EBL3379066
(CaPaEBR)ebr10863714
(OCoLC)829421146
collection bib_alma
record_format marc
spelling Institute of Medicine (U.S.). Forum on Drug Discovery, Development, and Translation, issuing body.
Maximizing the impact of the Cures Acceleration Network : accelerating the development of new drugs and diagnostics : workshop summary / Steve Olson and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies.
Accelerating the development of new drugs and diagnostics
Washington, District of Columbia : National Academies Press, [2012]
2012
1 online resource (131 pages)
text rdacontent
computer rdamedia
online resource rdacarrier
Includes bibliographical references (pages 71).
Introduction [The history and goals of CAN (Cures Acceleration Network)] -- Approaches to accelerating translational science -- Application of matching authority -- Application of flexible research authority -- Situating CAN within the drug development ecosystem -- Final reflections on ways to maximize the goals of CAN.
Advances in technologies and knowledge are creating new avenues for research and opportunities for the discovery and clinical development of innovative therapies and diagnostics. However, despite these opportunities, only a small fraction of investigational products are successfully developed into cures and therapies that can be accessed by patients. One response to the ever-widening gap between the number and promise of basic scientific discoveries and the translation of those discoveries into therapies is a renewed emphasis on collaborative approaches among federal agencies, academia, and industry, all directed at the advancement of the drug development enterprise. The newly developed Cures Acceleration Network (CAN)-a part of the National Center for Advancing Translational Sciences (NCATS) within the National Institutes of Health (NIH)-has the potential to catalyze widespread changes in NCATS, NIH, and the drug development ecosystem in general. On June 4-5, 2012, the IOM Forum on Drug Discovery, Development, and Translation held, at the request of NCATS, a workshop-bringing together members of federal government agencies, the private sector, academia, and advocacy groups-to explore options and opportunities in the implementation of CAN. Accelerating the Development of New Drugs and Diagnostics: Maximizing the Impact of the Cures Acceleration Network: Workshop Summary summarizes the workshop."--Publisher's description.
Description based on print version record.
Electronic reproduction. Ann Arbor, MI : ProQuest, 2015. Available via World Wide Web. Access may be limited to ProQuest affiliated libraries.
United States. Institutes of Health. National Center for Advancing Translational Sciences. Cures Acceleration Network.
Drug monitoring.
Drug development United States.
Drugs United States Design.
Pharmaceutical industry United States Quality control.
Electronic books.
Olson, Steve, 1956- contributor.
Claiborne, Anne B., contributor.
National Institute of Medicine (U.S.). Board on Health Sciences Policy, issuing body.
Print version: Institute of Medicine (U.S.). Maximizing the impact of the Cures Acceleration Network : accelerating the development of new drugs and diagnostics : workshop summary. Washington, District of Columbia : National Academies Press, [2012] xvi, 115 pages ; 23 cm 9780309261166 (OCoLC)ocn811963294 (DLC)10863714
ProQuest (Firm)
https://ebookcentral.proquest.com/lib/oeawat/detail.action?docID=3379066 Click to View
language English
format eBook
author2 Olson, Steve, 1956-
Claiborne, Anne B.,
National Institute of Medicine (U.S.). Board on Health Sciences Policy,
author_facet Olson, Steve, 1956-
Claiborne, Anne B.,
National Institute of Medicine (U.S.). Board on Health Sciences Policy,
author2_variant s o so
a b c ab abc
author2_role TeilnehmendeR
TeilnehmendeR
TeilnehmendeR
title Maximizing the impact of the Cures Acceleration Network : accelerating the development of new drugs and diagnostics : workshop summary /
spellingShingle Maximizing the impact of the Cures Acceleration Network : accelerating the development of new drugs and diagnostics : workshop summary /
Introduction [The history and goals of CAN (Cures Acceleration Network)] -- Approaches to accelerating translational science -- Application of matching authority -- Application of flexible research authority -- Situating CAN within the drug development ecosystem -- Final reflections on ways to maximize the goals of CAN.
title_sub accelerating the development of new drugs and diagnostics : workshop summary /
title_full Maximizing the impact of the Cures Acceleration Network : accelerating the development of new drugs and diagnostics : workshop summary / Steve Olson and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies.
title_fullStr Maximizing the impact of the Cures Acceleration Network : accelerating the development of new drugs and diagnostics : workshop summary / Steve Olson and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies.
title_full_unstemmed Maximizing the impact of the Cures Acceleration Network : accelerating the development of new drugs and diagnostics : workshop summary / Steve Olson and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies.
title_auth Maximizing the impact of the Cures Acceleration Network : accelerating the development of new drugs and diagnostics : workshop summary /
title_alt Accelerating the development of new drugs and diagnostics
title_new Maximizing the impact of the Cures Acceleration Network :
title_sort maximizing the impact of the cures acceleration network : accelerating the development of new drugs and diagnostics : workshop summary /
publisher National Academies Press,
publishDate 2012
physical 1 online resource (131 pages)
contents Introduction [The history and goals of CAN (Cures Acceleration Network)] -- Approaches to accelerating translational science -- Application of matching authority -- Application of flexible research authority -- Situating CAN within the drug development ecosystem -- Final reflections on ways to maximize the goals of CAN.
isbn 9780309261173
9780309261166
callnumber-first R - Medicine
callnumber-subject RM - Therapeutics and Pharmacology
callnumber-label RM302
callnumber-sort RM 3302 I58 42012
genre Electronic books.
genre_facet Electronic books.
geographic_facet United States.
United States
url https://ebookcentral.proquest.com/lib/oeawat/detail.action?docID=3379066
illustrated Not Illustrated
dewey-hundreds 600 - Technology
dewey-tens 610 - Medicine & health
dewey-ones 615 - Pharmacology & therapeutics
dewey-full 615.1/9
dewey-sort 3615.1 19
dewey-raw 615.1/9
dewey-search 615.1/9
oclc_num 829421146
work_keys_str_mv AT instituteofmedicineusforumondrugdiscoverydevelopmentandtranslation maximizingtheimpactofthecuresaccelerationnetworkacceleratingthedevelopmentofnewdrugsanddiagnosticsworkshopsummary
AT olsonsteve maximizingtheimpactofthecuresaccelerationnetworkacceleratingthedevelopmentofnewdrugsanddiagnosticsworkshopsummary
AT claiborneanneb maximizingtheimpactofthecuresaccelerationnetworkacceleratingthedevelopmentofnewdrugsanddiagnosticsworkshopsummary
AT nationalinstituteofmedicineusboardonhealthsciencespolicy maximizingtheimpactofthecuresaccelerationnetworkacceleratingthedevelopmentofnewdrugsanddiagnosticsworkshopsummary
AT instituteofmedicineusforumondrugdiscoverydevelopmentandtranslation acceleratingthedevelopmentofnewdrugsanddiagnostics
AT olsonsteve acceleratingthedevelopmentofnewdrugsanddiagnostics
AT claiborneanneb acceleratingthedevelopmentofnewdrugsanddiagnostics
AT nationalinstituteofmedicineusboardonhealthsciencespolicy acceleratingthedevelopmentofnewdrugsanddiagnostics
status_str n
ids_txt_mv (MiAaPQ)5003379066
(Au-PeEL)EBL3379066
(CaPaEBR)ebr10863714
(OCoLC)829421146
is_hierarchy_title Maximizing the impact of the Cures Acceleration Network : accelerating the development of new drugs and diagnostics : workshop summary /
author2_original_writing_str_mv noLinkedField
noLinkedField
noLinkedField
_version_ 1792330867234832384
fullrecord <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04517nam a2200529 i 4500</leader><controlfield tag="001">5003379066</controlfield><controlfield tag="003">MiAaPQ</controlfield><controlfield tag="005">20200520144314.0</controlfield><controlfield tag="006">m o d | </controlfield><controlfield tag="007">cr cnu||||||||</controlfield><controlfield tag="008">130212t20122012dcu ob 100 0 eng|d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9780309261166 (pbk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">0309261163 (pbk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780309261173</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(MiAaPQ)5003379066</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(Au-PeEL)EBL3379066</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CaPaEBR)ebr10863714</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)829421146</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">MiAaPQ</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="e">pn</subfield><subfield code="c">MiAaPQ</subfield><subfield code="d">MiAaPQ</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RM302</subfield><subfield code="b">.I58 2012</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615.1/9</subfield><subfield code="2">23</subfield></datafield><datafield tag="110" ind1="2" ind2=" "><subfield code="a">Institute of Medicine (U.S.).</subfield><subfield code="b">Forum on Drug Discovery, Development, and Translation,</subfield><subfield code="e">issuing body.</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Maximizing the impact of the Cures Acceleration Network :</subfield><subfield code="b">accelerating the development of new drugs and diagnostics : workshop summary /</subfield><subfield code="c">Steve Olson and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies.</subfield></datafield><datafield tag="246" ind1="3" ind2="0"><subfield code="a">Accelerating the development of new drugs and diagnostics</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Washington, District of Columbia :</subfield><subfield code="b">National Academies Press,</subfield><subfield code="c">[2012]</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">2012</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (131 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references (pages 71).</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Introduction [The history and goals of CAN (Cures Acceleration Network)] -- Approaches to accelerating translational science -- Application of matching authority -- Application of flexible research authority -- Situating CAN within the drug development ecosystem -- Final reflections on ways to maximize the goals of CAN.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Advances in technologies and knowledge are creating new avenues for research and opportunities for the discovery and clinical development of innovative therapies and diagnostics. However, despite these opportunities, only a small fraction of investigational products are successfully developed into cures and therapies that can be accessed by patients. One response to the ever-widening gap between the number and promise of basic scientific discoveries and the translation of those discoveries into therapies is a renewed emphasis on collaborative approaches among federal agencies, academia, and industry, all directed at the advancement of the drug development enterprise. The newly developed Cures Acceleration Network (CAN)-a part of the National Center for Advancing Translational Sciences (NCATS) within the National Institutes of Health (NIH)-has the potential to catalyze widespread changes in NCATS, NIH, and the drug development ecosystem in general. On June 4-5, 2012, the IOM Forum on Drug Discovery, Development, and Translation held, at the request of NCATS, a workshop-bringing together members of federal government agencies, the private sector, academia, and advocacy groups-to explore options and opportunities in the implementation of CAN. Accelerating the Development of New Drugs and Diagnostics: Maximizing the Impact of the Cures Acceleration Network: Workshop Summary summarizes the workshop."--Publisher's description.</subfield></datafield><datafield tag="588" ind1=" " ind2=" "><subfield code="a">Description based on print version record.</subfield></datafield><datafield tag="590" ind1=" " ind2=" "><subfield code="a">Electronic reproduction. Ann Arbor, MI : ProQuest, 2015. Available via World Wide Web. Access may be limited to ProQuest affiliated libraries.</subfield></datafield><datafield tag="610" ind1="1" ind2="0"><subfield code="a">United States.</subfield><subfield code="b">Institutes of Health.</subfield><subfield code="b">National Center for Advancing Translational Sciences.</subfield><subfield code="b">Cures Acceleration Network.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Drug monitoring.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Drug development</subfield><subfield code="z">United States.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Drugs</subfield><subfield code="z">United States</subfield><subfield code="x">Design.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Pharmaceutical industry</subfield><subfield code="z">United States</subfield><subfield code="x">Quality control.</subfield></datafield><datafield tag="655" ind1=" " ind2="4"><subfield code="a">Electronic books.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Olson, Steve,</subfield><subfield code="d">1956-</subfield><subfield code="e">contributor.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Claiborne, Anne B.,</subfield><subfield code="e">contributor.</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">National Institute of Medicine (U.S.).</subfield><subfield code="b">Board on Health Sciences Policy,</subfield><subfield code="e">issuing body.</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="a">Institute of Medicine (U.S.).</subfield><subfield code="t">Maximizing the impact of the Cures Acceleration Network : accelerating the development of new drugs and diagnostics : workshop summary.</subfield><subfield code="d">Washington, District of Columbia : National Academies Press, [2012]</subfield><subfield code="h">xvi, 115 pages ; 23 cm</subfield><subfield code="z">9780309261166</subfield><subfield code="w">(OCoLC)ocn811963294</subfield><subfield code="w">(DLC)10863714</subfield></datafield><datafield tag="797" ind1="2" ind2=" "><subfield code="a">ProQuest (Firm)</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://ebookcentral.proquest.com/lib/oeawat/detail.action?docID=3379066</subfield><subfield code="z">Click to View</subfield></datafield></record></collection>